Pulmonx (NASDAQ:LUNG – Get Free Report) is set to issue its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.
Pulmonx (NASDAQ:LUNG – Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. The business had revenue of $20.78 million for the quarter, compared to analyst estimates of $20.23 million. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Pulmonx Stock Down 1.0 %
LUNG opened at $6.03 on Monday. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37. The firm has a market cap of $234.06 million, a P/E ratio of -3.92 and a beta of 0.64. Pulmonx has a 52 week low of $5.46 and a 52 week high of $14.84. The business’s fifty day simple moving average is $7.30 and its 200 day simple moving average is $7.29.
Analysts Set New Price Targets
Check Out Our Latest Analysis on Pulmonx
Insider Buying and Selling
In other news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the transaction, the director now directly owns 1,111,974 shares in the company, valued at $8,995,869.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the transaction, the director now directly owns 1,111,974 shares in the company, valued at $8,995,869.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven S. Williamson acquired 14,245 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was purchased at an average price of $6.84 per share, for a total transaction of $97,435.80. Following the completion of the acquisition, the chief executive officer now owns 219,531 shares in the company, valued at approximately $1,501,592.04. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 50,351 shares of company stock worth $361,494. 5.70% of the stock is owned by company insiders.
Pulmonx Company Profile
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
See Also
- Five stocks we like better than Pulmonx
- The 3 Best Blue-Chip Stocks to Buy Now
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is a Secondary Public Offering? What Investors Need to Know
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Are the U.K. Market Holidays? How to Invest and Trade
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.